Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC.PVLA · Entity 4452 | Chief Operating Officer | September 16, 2026 | September 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PALVELLA THERAPEUTICS, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-16 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-09-16 · Exercise / conversion · Acquired 2,154 · Balance 2,154 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Row 2 · 2026-09-16 · Exercise / conversion · Acquired 2,148 · Balance 4,302 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Row 3 · 2026-09-16 · Sale · Disposed 1,659 · Balance 2,643 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.755 to $151.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 4 · 2026-09-16 · Sale · Disposed 989 · Balance 1,654 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.77 to $152.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Row 5 · 2026-09-16 · Sale · Disposed 1,654 · Balance 0 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.78 to $153.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.14 · Expires 2029-10-29 | Direct | 2,165 |
Reported balance
After 2026-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-16 · Exercise / conversion · Disposed 2,154 · Balance 2,165 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5: The stock option is fully vested. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.08 · Expires 2030-10-14 | Direct | 2,148 |
Reported balance
After 2026-09-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-16 · Exercise / conversion · Disposed 2,148 · Balance 2,148 F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F5: The stock option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $150.755 to $151.74, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $151.77 to $152.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $152.78 to $153.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
F5: The stock option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,730 | $118.37 | $204,776.81 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.00 to $118.81, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,268 | $117.56 | $266,633.34 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,034 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $116.995 to $117.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| March 18, 2026 Filed Mar 20, 2026 20:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-032695 · tm269404-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,184 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · derivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,243 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,276 | $79.97 | $102,035.47 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $79.775 to $80.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 3,026 | $79.16 | $239,528.78 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,276 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $78.75 to $79.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-018136 · tm266892-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| February 05, 2026 Filed Feb 9, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (Right to Buy) · Derivative | 48,956 | $0.00 Strike: $76.43 | $0.00 |
DisclosureSEC source: 0001104659-26-012060 · tm265512-1_4seq1.xml · derivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,956 Underlying: Common Stock · 48,956 shares Expires 2036-02-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in equal monthly installments over 48 months commencing from February 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,332 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · derivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,397 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 3,749 | $97.94 | $367,177.06 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 553 | $95.49 | $52,805.97 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,749 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-26-006237 · tm263925-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-25-123109 · tm2534005-1_4seq1.xml · derivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,480 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-25-123109 · tm2534005-1_4seq1.xml · derivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,551 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F3 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 4,302 | $96.47 | $415,022.54 |
DisclosureSEC source: 0001104659-25-123109 · tm2534005-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.34 to $96.82. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-25-123109 · tm2534005-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| December 17, 2025 Filed Dec 19, 2025 21:05 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-25-123109 · tm2534005-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,148 | $0.00 Strike: $9.08 | $0.00 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · derivative · entry 6 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,628 Underlying: Common Stock · 2,148 shares Expires 2030-10-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,154 | $0.00 Strike: $7.14 | $0.00 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · derivative · entry 5 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,705 Underlying: Common Stock · 2,154 shares Expires 2029-10-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. F4 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 2,802 | $86.51 | $242,387.85 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · nonDerivative · entry 4 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $86.485 to $86.97. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | SaleCommon Stock | 1,500 | $85.72 | $128,577.45 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · nonDerivative · entry 3 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,802 F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $85.475 to $86.08. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,148 | $9.08 | $19,503.84 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · nonDerivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,302 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. Read SEC document |
| November 19, 2025 Filed Nov 21, 2025 21:25 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | Exercise / conversionCommon Stock | 2,154 | $7.14 | $15,379.56 |
DisclosureSEC source: 0001104659-25-115017 · tm2531981-1_4seq1.xml · nonDerivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. Read SEC document |
| February 05, 2025 Filed Feb 10, 2025 22:40 UTC Amendment | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 123,559 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0001583648-25-000019 · edgardoc.xml · derivative · entry 2 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,559 Underlying: Common Stock · 123,559 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document |
| February 05, 2025 Filed Feb 10, 2025 22:40 UTC Amendment | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantIncentive Stock Option (right to buy) · Derivative | 5,373 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0001583648-25-000019 · edgardoc.xml · derivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,373 Underlying: Common Stock · 5,373 shares Expires 2035-02-05 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months Read SEC document |
| December 13, 2024 Filed Dec 18, 2024 01:43 UTC | PALVELLA THERAPEUTICS, INC. PVLA · Entity 4452 | GrantStock Option (right to buy) · Derivative | 27,843 | $0.00 Strike: $13.60 | $0.00 |
DisclosureSEC source: 0001062993-24-020819 · form4.xml · derivative · entry 1 Goin Kathleen · CIK 0001912570 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,843 Underlying: Common Stock · 27,843 shares Expires 2034-12-13 F1 · derivative.exercise_date: The stock options will vest in equal monthly tranches over 48 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.